These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 9510119)

  • 41. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
    Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
    Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TSH receptor antibody measurements and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs.
    Okamoto Y; Tanigawa S; Ishikawa K; Hamada N
    Endocr J; 2006 Aug; 53(4):467-72. PubMed ID: 16820704
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The mechanism of spontaneous hypothyroidism in patients with Graves' disease after antithyroid drug treatment.
    Tamai H; Hirota Y; Kasagi K; Matsubayashi S; Kuma K; Iida Y; Konishi J; Okimura MC; Walter RM; Kumagai LF
    J Clin Endocrinol Metab; 1987 Apr; 64(4):718-22. PubMed ID: 2434520
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Antibodies against TSH receptors (TRAb) as indicators in prognosing the effectiveness of Tiamazol therapy for Grave's Disease].
    Bojarska-Szmygin A; Ciechanek R
    Wiad Lek; 2003; 56(7-8):303-7. PubMed ID: 14969154
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thyroid vascularization by color doppler ultrasonography in Graves' disease. Changes related to different phases and to the long-term outcome of the disease.
    Baldini M; Castagnone D; Rivolta R; Meroni L; Pappalettera M; Cantalamessa L
    Thyroid; 1997 Dec; 7(6):823-8. PubMed ID: 9459623
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predicting a relapse of Graves' hyperthyroidism in adults during the early phase of treatment with anti-thyroid drugs.
    Jonas M; Ambroziak U; Bednarczuk T; Nauman J
    Endokrynol Pol; 2006; 57(6):596-604. PubMed ID: 17253432
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease.
    Kashiwai T; Hidaka Y; Takano T; Tatsumi KI; Izumi Y; Shimaoka Y; Tada H; Takeoka K; Amino N
    Endocr J; 2003 Feb; 50(1):45-9. PubMed ID: 12733708
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease.
    Schott M; Minich WB; Willenberg HS; Papewalis C; Seissler J; Feldkamp J; Bergmann A; Scherbaum WA; Morgenthaler NG
    Horm Metab Res; 2005 Dec; 37(12):741-4. PubMed ID: 16372227
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Specific effects of radioiodine treatment on TSAb and TBAb levels in patients with Graves' disease.
    Michelangeli VP; Poon C; Topliss DJ; Colman PG
    Thyroid; 1995 Jun; 5(3):171-6. PubMed ID: 7580264
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Juvenile Graves disease: usefulness and limitations of thyrotropin receptor antibody determinations.
    Foley TP; White C; New A
    J Pediatr; 1987 Mar; 110(3):378-86. PubMed ID: 2880956
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
    Glinoer D; de Nayer P; Bex M;
    Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High cut-off value of a chimeric TSH receptor (Mc4)-based bioassay may improve prediction of relapse in Graves' disease for 12 months.
    Hwang S; Shin DY; Song MK; Lee EJ
    Endocrine; 2015 Feb; 48(1):89-95. PubMed ID: 24968734
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Simultaneous assay for three types of thyrotropin receptor antibody activities using FRTL-5 cells in patients with autoimmune thyroid diseases.
    Zhu Y; Portmann L; Dénéréaz N; Lemarchand-Béraud T
    Eur J Endocrinol; 1994 Oct; 131(4):359-68. PubMed ID: 7921224
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outcome Prediction of Treatment of Graves' Hyperthyroidism with Antithyroid Drugs.
    Piantanida E; Lai A; Sassi L; Gallo D; Spreafico E; Tanda ML; Bartalena L
    Horm Metab Res; 2015 Sep; 47(10):767-72. PubMed ID: 26197855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection of low titre TBII in patients with Graves' disease using recombinant human TSH receptor.
    Morgenthaler NG; Nagata A; Katayama S; Bergmann A; Iitaka M
    Clin Endocrinol (Oxf); 2002 Aug; 57(2):193-8. PubMed ID: 12153597
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic value of thyrotrophin binding inhibiting immunoglobulins (TBII) in longterm antithyroid treatment, 131I therapy given in combination with carbimazole and in euthyroid ophthalmopathy.
    Bliddal H; Kirkegaard C; Siersbaek-Nielsen K; Friis T
    Acta Endocrinol (Copenh); 1981 Nov; 98(3):364-9. PubMed ID: 6170200
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
    Schott M; Morgenthaler NG; Fritzen R; Feldkamp J; Willenberg HS; Scherbaum WA; Seissler J
    Horm Metab Res; 2004 Feb; 36(2):92-6. PubMed ID: 15002058
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Early Changes in Thyroid-Stimulating Immunoglobulin Bioassay over Anti-Thyroid Drug Treatment Could Predict Prognosis of Graves' Disease.
    Yu J; Baek HS; Jeong C; Jo K; Lee J; Ha J; Kim MH; Lee J; Lim DJ
    Endocrinol Metab (Seoul); 2023 Jun; 38(3):338-346. PubMed ID: 37291744
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Changes in thyroid-stimulating antibody activity in Graves' disease treated with antithyroid drug and its relationship to relapse: a prospective study.
    Teng CS; Yeung RT
    J Clin Endocrinol Metab; 1980 Jan; 50(1):144-7. PubMed ID: 6892512
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic value of thyroid stimulating antibodies and TSH-binding inhibiting immunoglobulins in the follow-up of Graves' disease.
    Hörmann R; Saller B; Müller R; Mann K
    Klin Wochenschr; 1985 Dec; 63(24):1247-52. PubMed ID: 2868149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.